The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
Authors
Keywords
-
Journal
Therapeutic Advances in Musculoskeletal Disease
Volume 10, Issue 5-6, Pages 105-115
Publisher
SAGE Publications
Online
2018-06-07
DOI
10.1177/1759720x18775936
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
- (2018) David L Kendler et al. LANCET
- Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
- (2017) Tony M Keaveny et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
- (2016) Harry K Genant et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys
- (2016) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study
- (2016) Luc Chouinard et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice
- (2015) Michelle L. Thompson et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength
- (2015) W. Yao et al. OSTEOPOROSIS INTERNATIONAL
- Future directions for new medical entities in osteoporosis
- (2014) Serge Ferrari BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
- (2014) Xiaodong Li et al. ENDOCRINOLOGY
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study
- (2013) Desmond Padhi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury
- (2012) Martine Roudier et al. ARTHRITIS AND RHEUMATISM
- Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers
- (2012) Antoon H van Lierop et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Osteocyte regulation of bone mineral: a little give and take
- (2012) G. J. Atkins et al. OSTEOPOROSIS INTERNATIONAL
- Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
- (2011) Xiaodong Li et al. ENDOCRINOLOGY
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
- (2011) Asiri R. Wijenayaka et al. PLoS One
- Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength
- (2010) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats
- (2010) Xiaodong Li et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
- (2010) Desmond Padhi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
- (2008) Paul D. Miller et al. BONE
- Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*
- (2008) Xiaodong Li et al. JOURNAL OF BONE AND MINERAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now